Assertio Holdings Inc. Common Stock (ASRT)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style balance-sheet and cash-flow exercise. Assertio sells specialty generic and branded prescription medicines, including INDOCIN and Sympazan, with only 53 employees. In the latest reported quarter, fiscal Q1 2026, revenue was $9.9 million and net income was -$18.9 million, a -189.83% net margin. That is not the profile of a durable business. Trailing free cash flow is -$7.1 million, and the FCF yield is -6.1%, so the company is consuming cash. At the 2026-06-26 close of $23.50, market capitalization is $116.5 million. FairStock's calculations show a P/E of -4.23, P/B of 2.00, ROE of -38.76%, ROCE of -5.71%, and debt-to-equity of 0.53. Paying twice book for negative returns is not a margin of safety. The Altman Z-Score of -4.08 suggests financial distress risk, while the Piotroski F-Score of 3/9 and FairStock Score of 32/100 confirm weak fundamentals. The reported revenue growth is -62.5% and profit growth is -39.25%, so the trend is shrinking, not compounding. The Lynch category is 'none' because there are only 0 years of filed annual results and three are needed. A low beta of 0.53 may mean less volatility, but volatility is not the same as safety. Without evidence of stable revenue, positive cash flow, and a discount to intrinsic value, this looks speculative rather than investment-grade.

In plain English: Assertio Holdings sells prescription medicines, including treatments for arthritis and seizures. The business looks weak right now: it lost money in its latest quarter, sales have fallen sharply, and cash flow is negative. At $23.50, the stock is near its 52-week high, so based on the reported numbers it looks expensive rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-06-26 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer